You are here

JNJ

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis

Biopharma Reporter

Thu, 11/9/23 - 09:55 am

rheumatoid arthritis

clinical trials

J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina

Fierce Pharma

Wed, 11/8/23 - 09:57 pm

Fujifilm Diosynth Biotechnologies

J&J targets 2024 for Ottava FDA filing

Medtech Dive

Tue, 11/7/23 - 11:05 pm

robotic surgery

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

BioSpace

Tue, 11/7/23 - 09:48 am

Inflation Reduction Act

Study of Johnson & Johnson device shows promising results for AFib

Clinical Trials Arena

Fri, 11/3/23 - 10:54 am

atrial fibrillation

Amgen scores FDA approval for Stelara biosimilar

Pharmaceutical Technology

Wed, 11/1/23 - 10:16 pm

GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

Reuters

Tue, 10/31/23 - 10:18 am

Cidara’s J&J-partnered immunotherapy could target flu and cancer

Pharma Voice

Thu, 10/26/23 - 10:35 am

drug-Fc conjugates

Janssen reports data from Phase III trial of lung cancer drug

Clinical Trials Arena

Tue, 10/24/23 - 10:21 am

clinical trials

non-small cell lung cancer

J&J bites back against dengue, linking antiviral to protection from infection in challenge trial

Fierce Biotech

Fri, 10/20/23 - 10:15 am

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

OBR Oncology

Fri, 10/20/23 - 10:05 am

non-small cell lung cancer

Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?

Medical Marketing and Media

Thu, 10/19/23 - 11:29 am

EGFR-mutated NSCLC

After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti

Fierce Pharma

Wed, 10/18/23 - 07:44 pm

Multiple Myeloma

Why Johnson & Johnson Stock Flopped Today

Motley Fool

Wed, 10/18/23 - 07:39 pm

J&J Signals Exit from Less Profitable Orthopedic Markets

Medical Devices and Diagnostics Industry

Wed, 10/18/23 - 10:14 am

J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance

BioSpace

Tue, 10/17/23 - 09:39 pm

Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial

Clinical Trials Arena

Tue, 10/17/23 - 11:45 am

clinical trials

Crohn's Disease

FDA Warning Letter to J&J's Abiomed Has Broad Implications for Medtech

Medical Devices and Diagnostics Industry

Tue, 10/17/23 - 10:20 am

warning letters

AbbVie trumpets Skyrizi's resounding win against J&J's Stelara in Crohn's disease

Fierce Pharma

Mon, 10/16/23 - 11:50 am

Crohn's Disease

FDA Rejects Alvotech’s Stelara Biosimilar as Manufacturing Problems Continue

BioSpace

Thu, 10/12/23 - 10:22 am

Pages